Flavopiridol, the first cyclin-dependent kinase inhibitor: Recent advances in combination chemotherapy

Mini-Reviews in Medicinal Chemistry

Volumn 10, Issue 11, 2010, Pages 1058-1070

  Wang, L M ^a   Ren, D M ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Anticancer; Cancer; CDKIs; Combination therapy; Flavonoid; Flavopiridol

Indexed keywords

2 FLUOROPHENYL; 5 METHYLISOXAZOLE; 7 HYDROXYSTAUROSPORINE; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORTEZOMIB; BRYOSTATIN; BUTYRIC ACID; CYCLIN DEPENDENT KINASE INHIBITOR; DEPSIPEPTIDE; DESCHLOROFLAVOPIRIDOL; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLAVOPIRIDOL; GEMCITABINE; GENISTEIN; HISTONE DEACETYLASE INHIBITOR; IMATINIB; ISOCOUMARIN DERIVATIVE; LACTACYSTIN; MINOCYCLINE; OXOFLAVOPIRIDOL; PACLITAXEL; PROTEASOME INHIBITOR; QUERCETIN; QUINOLONE DERIVATIVE; THIOFLAVOPIRIDOL; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORINOSTAT;

ALOPECIA; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; APOPTOSIS; ARTICLE; ASTHENIA; BREAST CANCER; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL DIFFERENTIATION; CELL PROLIFERATION; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONTINUOUS INFUSION; CYTOTOXICITY; DIARRHEA; DRUG POTENTIATION; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IC 50; INFECTION; IRRADIATION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MAXIMUM TOLERATED DOSE; METASTASIS; MUCOSA INFLAMMATION; MYALGIA; NAUSEA; NEUTROPENIA; NONHUMAN; PAIN; PANCREAS CANCER; PANCREAS CARCINOMA; RADIOSENSITIZATION; SOLID TUMOR; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION; TUMOR CELL; VIRUS REPLICATION;

EID: 77956637674     PISSN: 13895575     EISSN: None     Source Type: Journal    
DOI: 10.2174/1389557511009011058     Document Type: Article

References (112)

1. López-Lázaro, M. Flavonoids as anticancer agents: structure-activity relationship study. Curr. Med. Chem. Anticancer Agents., 2002, 2, 691-714.
2. Takada, Y.; Aggarwal, B.B. Flavopiridol inhibits NF-κB activation induced by various carcinogens and inflammatory agents through inhibition of I B kinase and p65 phosphorylation: abrogation of cyclin D1, cyclooxygenase-2, and matrix metalloprotease-9. J. Biol. Chem., 2004, 279, 4750-4759.
3. Kelland, L.R. Flavopiridol, the first cyclin-dependent kinase inhibitor to enter the clinic: current status. Expert. Opin. Investig. Drugs., 2000, 9, 2903-2911.
4. Shapiro, G.I. Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridol. Clin. Cancer Res., 2004, 10, 4270s-4275s.
5. König, A.; Schwartz, G.K.; Mohammad, R.M.; Al-Katib, A.; Gabrilove, J.L. The novel cyclin-dependent kinase inhibitor flavopiridol downregulates Bcl-2 and induces growth arrest and apoptosis in chronic B-cell leukemia lines. Blood, 1997, 90, 4307-4312.
6. Gojo, I.; Zhang, B.; Fenton, R.G. The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1. Clin. Cancer Res., 2002, 8, 3527-3538.
7. Kitada, S.; Zapata, J.M.; Andreeff, M.; Reed, J.C. Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia. Blood, 2000, 96, 393-397.
8. Wittmann, S.; Bali, P.; Donapaty, S.; Nimmanapalli, R.; Guo, F.; Yamaguchi, H.; Huang, M.; Jove, R.; Wang, H.G.; Bhalla, K. Flavopiridol down-regulates antiapoptotic proteins and sensitizes human breast cancer cells to epothilone B-induced apoptosis. Cancer Res., 2003, 63, 93-99.
9. Wu, K.; Wang, C.; D'Amico, M.; Lee, R.J.; Albanese, C.; Pestell, R.G.; Mani, S. Flavopiridol and trastuzumab synergistically inhibit proliferation of breast cancer cells: association with selective cooperative inhibition of cyclin D1-dependent kinase and Akt signaling pathways. Mol. Cancer Ther., 2002, 1, 695-706.
10. Carlson, B.; Lahusen, T.; Singh, S.; Loaiza-Perez, A.; Worland, P.J.; Pestell, R.; Albanese, C.; Sausville, E.A.; Senderowicz, A.M. Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol. Cancer Res., 1999, 59, 4634-4641.
11. Melillo, G.; Sausville, E.A.; Cloud, K.; Lahusen, T.; Varesio, L.; Senderowicz, A.M. Flavopiridol, a protein kinase inhibitor, downregulates hypoxic induction of vascular endothelial growth factor expression in human monocytes. Cancer Res., 1999, 59, 5433-5437.
12. Motwani, M.; Delohery, T.M.; Schwartz, G.K. Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells. Clin. Cancer Res., 1999, 5, 1876-1883.
13. Bible, K.C.; Kaufmann, S.H. Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: the importance of sequence of administration. Cancer Res., 1997, 57, 3375-3380.
14. Patel, V.; Senderowicz, A.M.; Pinto, D.Jr.; Igishi, T.; Raffeld, M.; Quintanilla-Martinez, L.; Ensley, J.F.; Sausville, E.A.; Gutkind, J.S. Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis. J. Clin. Invest., 1998, 102, 1674-1681.
15. Jung, C.; Motwani, M.; Kortmansky, J.; Sirotnak, F.M.; She, Y.; Gonen, M.; Haimovitz-Friedman, A.; Schwartz, G.K. The cyclindependent kinase inhibitor flavopiridol potentiates γ-irradiation-induced apoptosis in colon and gastric cancer cells. Clin. Cancer Res., 2003, 9, 6052-6061.
16. Sato, S.; Kajiyama, Y.; Sugano, M.; Iwanuma, Y.; Tsurumaru, M. Flavopiridol as a radio-sensitizer for esophageal cancer cell lines. Dis. Esophagus., 2004, 17, 338-344.
17. Matranga, C.B.; Shapiro, G.I. Selective sensitization of trans-formed cells to flavopiridol-induced apoptosis following recruitment to S-phase. Cancer Res., 2002, 62, 1707-1717.
18. Motwani, M.; Rizzo, C.; Sirotnak, F.; She, Y.; Schwartz, G.K. Flavopiridol enhances the effect of docetaxel in vitro and in vivo in human gastric cancer cells. Mol. Cancer Ther., 2003, 2, 549-555.
19. Fornier, M.N.; Rathkopf, D.; Shah, M.; Patil, S.; O'Reilly, E.; Tse, A.N.; Hudis, C.; Lefkowitz, R.; Kelsen, D.P.; Schwartz, G.K. Phase I dose-finding study of weekly docetaxel followed by flavopiridol for patients with advanced solid tumors. Clin. Cancer Res., 2007, 13, 5841-5846.
20. Bible, K.C.; Lensing, J.L.; Nelson, S.A.; Lee, Y.K.; Reid, J.M.; Ames, M.M.; Isham, C.R.; Piens, J.; Rubin, S.L.; Rubin, J.; Kaufmann, S.H.; Atherton, P.J.; Sloan, J.A.; Daiss, M.K.; Adjei, A.A.; Erlichman, C. Phase I trial of flavopiridol combined with cisplatin or carboplatin in patients with advanced malignancies with the assessment of pharmacokinetic and pharmacodynamic end points. Clin. Cancer Res., 2005, 11, 5935-5941.
21. Mitchell, C.; Park, M.A.; Zhang, G.; Yacoub, A.; Curiel, D.T.; Fisher, P.B.; Roberts, J.D.; Grant, S.; Dent, P. Extrinsic pathway-and cathepsin-dependent induction of mitochondrial dysfunction are essential for synergistic flavopiridol and vorinostat lethality in breast cancer cells. Mol. Cancer Ther., 2007, 6, 3101-3112.
22. Kim, D.M.; Koo, S.Y.; Jeon, K.; Kim, M.H.; Lee, J.; Hong, C.Y.; Jeong, S. Rapid induction of apoptosis by combination of flavopiridol and tumor necrosis factor (TNF)-α or TNF-related apoptosis-inducing ligand in human cancer cell lines. Cancer Res., 2003, 63, 621-626.
23. Pei, X.Y.; Dai, Y.; Grant, S. The small-molecule Bcl-2 inhibitor HA14-1 interacts synergistically with flavopiridol to induce mitochondrial injury and apoptosis in human myeloma cells through a free radical-dependent and Jun NH2-terminal kinase-dependent mechanism. Mol. Cancer Ther., 2004, 3, 1513-1524.
24. Mohanakumara, P.; Sreejayan, N.; Priti, V.; Ramesha, B.T.; Ravikanth, G.; Ganeshaiah, K.N.; Vasudeva, R.; Mohan, J.; Santhoshkumar, T.R.; Mishra, P.D.; Ram, V.; Shaanker, R.U. Dysoxylum binectariferum Hook.f (Meliaceae), a rich source of rohitukine. Fitoterapia., 2010, 81, 145-148.
25. Kim, K.S.; Sack, J.S.; Tokarski, J.S.; Qian, L.; Chao, S.T.; Leith, L.; Kelly, Y.F.; Misra, R.N.; Hunt, J.T.; Kimball, S.D.; Humphreys, W.G.; Wautlet, B.S.; Mulheron, J.G.; Webster, K.R. Thio- and oxoflavopiridols, cyclin-dependent kinase 1-selective inhibitors: synthesis and biological effects. J. Med. Chem., 2000, 43, 4126-4134.
26. Murthi, K.K.; Dubay, M.; McClure, C.; Brizuela, L.; Boisclair, M.D.; Worland, P.J.; Mansuri, M.M.; Pal, K. Structure-activity relationship studies of flavopiridol analogues. Bioorg. Med. Chem. Lett., 2000, 10, 1037-1041.
27. Gross, A.; Borcherding, D.R.; Friedrich, D.; Sabol, J.S. A stereo-controlled approach to substituted piperidones and piperidines: flavopiridol D-ring analogs. Tetrahedron. Lett., 2001, 42, 1631-1633.
28. Ali, A.; Ghosh, A.; Nathans, R.S.; Sharova, N.; O'Brien, S.; Cao, H.; Stevenson, M.; Rana, T.M. Identification of flavopiridol analogues that selectively inhibit positive transcription elongation factor (P-TEFb) and block HIV-1 replication. ChemBioChem., 2009, 10, 2072-2080.
29. Schoepfer, J.; Fretz, H.; Chaudhuri, B.; Muller, L.; Seeber, E.; Meijer, L.; Lozach, O.; Vangrevelinghe, E.; Furet, P. Structure-based design and synthesis of 2-benzylidene-benzofuran-3-ones as flavopiridol mimics. J. Med. Chem., 2002, 45, 1741-1747.
30. Deep, G.; Agarwal, R. New combination therapies with cell-cycle agents. Curr. Opin. Investig. Drugs., 2008, 9, 591-604.
31. Vermeulen, K.; Van Bockstaele, D.R.; Berneman, Z.N. The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell. Prolif., 2003, 36, 131-149.
32. Mihara, M.; Shintani, S.; Nakashiro, K.; Hamakawa, H. Flavopiridol, a cyclin dependent kinase (CDK) inhibitor, induces apoptosis by regulating Bcl-x in oral cancer cells. Oral. Oncol., 2003, 39, 49-55.
33. Pines, J. Cyclins and cyclin-dependent kinases: theme and variations. Adv. Cancer Res., 1995, 66, 181-212.
34. Atherton-Fessler, S.; Parker, L.L.; Geahlen, R.L.; Piwnica-Worms, H. Mechanisms of p34cdc2 regulation. Mol. Cell. Biol., 1993, 13, 1675-1685.
35. Benson, C.; Kaye, S.; Workman, P.; Garrett, M.; Walton, M.; de Bono, J. Clinical anticancer drug development: targeting the cyclin-dependent kinases. Br. J. Cancer, 2005, 92, 7-12.
36. Dai, Y.; Grant, S. Cyclin-dependent kinase inhibitors. Curr. Opin. Pharmacol., 2003, 3, 362-370.
37. Senderowicz, A.M.; Sausville, E.A. Preclinical and Clinical Development of Cyclin-Dependent Kinase Modulators. J. Natl. Cancer Inst., 2000, 92, 376-387.
38. Senderowicz, A.M. Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials. Invest. New. Drugs, 1999, 17, 313-320.
39. Sedlacek, H.H.; Czech, J.; Naik, R.; Kaur, G.; Worland, P.; Losiewicz, M.; Parker, B.; Carlson, B.; Smith, A.; Senderowicz, A.; Sausville, E. Flavopiridol (L86-8275, NSC-649890), a new kinase inhibitor for tumor therapy. Int. J. Oncol., 1996, 9, 1143-1168.
40. Carlson, B.; Pearlstein, R.; Naik, R.; Sedlacek, H.; Sausville, E.; Worland, P. Inhibition of CDK2, CDK4 and CDK7 by flavopiridol and structural analogs [abstract]. Proc. Am. Assoc. Cancer Res., 1996, 37, 424.
41. Carlson, B.A.; Dubay, M.M.; Sausville, E.A.; Brizuela, L.; Worland, P.J. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res., 1996, 56, 2973-2978.
42. Losiewicz, M.D.; Carlson, B.A.; Kaur, G.; Sausville, E.A.; Worland, P.J. Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275. Biochem. Biophys. Res. Commun., 1994, 201, 589-595.
43. Singh, S.S.; Sausville, E.A.; Senderowicz, A.M. Cyclin D1 and CDK6 are the targets for flavopiridol-mediated G1 block in MCF10A breast epithelial cell line [abstract]. Proc. Am. Assoc. Cancer Res., 1999, 40, 28.
44. Worland, P.J.; Kaur, G.; Stetler-Stevenson, M.; Sebers, S.; Sartor, O.; Sausville, E.A. Alteration of the phosphorylation state of p34cdc2 kinase by the flavone L86-8275 in breast carcinoma cells. Correlation with decreased H1 kinase activity. Biochem. Pharmacol., 1993, 46, 1831-1840.
45. Sedlacek, H.H. Mechanisms of action of flavopiridol. Crit. Rev. Oncol. Hematol., 2001, 38, 139-170.
46. Senderowicz, A.M. The cell cycle as a target for cancer therapy: basic and clinical findings with the small molecule inhibitors flavopiridol and UCN-01. Oncologist, 2002, 7(Suppl 3), 12-19.
47. Chao, S.H.; Fujinaga, K.; Marion, J.E.; Taube, R.; Sausville, E.A.; Senderowicz, A.M.; Peterlin, B.M.; Price, D.H. Flavopiridol inhibits P-TEFb and blocks HIV-1 replication. J. Biol. Chem., 2000, 275, 28345-28348.
48. Price, D.H. P-TEFb, a cyclin-dependent kinase controlling elongation by RNA polymerase II. Mol. Cell. Biol., 2000, 20, 2629-2634.
49. Monga, M.; Sausville, E.A. Developmental therapeutics program at the NCI: molecular target and drug discovery process. Leukemia, 2002, 16, 520-526.
50. Brüsselbach, S.; Nettelbeck, D.M.; Sedlacek, H.H.; Müller, R. Cell cycle-independent induction of apoptosis by the anti-tumor drug Flavopiridol in endothelial cells. Int. J. Cancer, 1998, 77, 146-152.
51. Kerr, J.S.; Wexler, R.S.; Mousa, S.A.; Robinson, C.S.; Wexler, E.J.; Mohamed, S.; Voss, M.E.; Devenny, J.J.; Czerniak, P.M.; Gudzelak, A. Jr.; Slee, A.M. Novel small molecule alpha v integrin antagonists: comparative anti-cancer efficacy with known angiogenesis inhibitors. Anti Cancer Res., 1999, 19, 959-968.
52. Byrd, J.C.; Shinn, C.; Waselenko, J.K.; Fuchs, E.J.; Lehman, T.A.; Nguyen, P.L.; Flinn, I.W.; Diehl, L.F.; Sausville, E.; Grever, M.R. Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53. Blood, 1998, 92, 3804-3816.
53. Pepper, C.; Thomas, A.; Hoy, T.; Fegan, C.; Bentley, P. Flavopiridol circumvents Bcl-2 family mediated inhibition of apoptosis and drug resistance in B-cell chronic lymphocytic leukaemia. Br. J. Haematol., 2001, 114, 70-77.
54. Ma, Y.; Cress, W.D.; Haura, E.B. Flavopiridol-induced apoptosis is mediated through up-regulation of E2F1 and repression of Mcl-1. Mol. Cancer Ther., 2003, 2, 73-81.
55. Lee, H.R.; Chang, T.H.; Tebalt, M.J. 3rd.; Senderowicz, A.M.; Szabo, E. Induction of differentiation accompanies inhibition of CDK2 in a non-small cell lung cancer cell line. Int. J. Oncol., 1999, 15, 161-166.
56. Gomez, L.A.; de Las Pozas, A.; Perez-Stable, C. Sequential combination of flavopiridol and docetaxel reduces the levels of X-linked inhibitor of apoptosis and AKT proteins and stimulates apoptosis in human LNCaP prostate cancer cells. Mol. Cancer Ther., 2006, 5, 1216-1226.
57. Reiner, T.; de las Pozas, A.; Perez-Stable, C. Sequential combinations of flavopiridol and docetaxel inhibit prostate tumors, induce apoptosis, and decrease angiogenesis in the G /T-15 transgenic mouse model of prostate cancer. Prostate, 2006, 66, 1487-1497.
58. Kim, J.C.; Saha, D.; Cao, Q.; Choy, H. Enhancement of radiation effects by combined docetaxel and flavopiridol treatment in lung cancer cells. Radiother. Oncol., 2004, 71, 213-221.
59. Carrozza, M.J.; Utley, R.T.; Workman, J.L.; Côté, J. The diverse functions of histone acetyltransferase complexes. Trends Genet., 2003, 19, 321-329.
60. Peterson, C.L. HDAC's at work: everyone doing their part. Mol. Cell., 2002, 9, 921-922.
61. Gray, S.G.; Teh, B.T. Histone acetylation/deacetylation and cancer: an open and shut case? Curr. Mol. Med., 2001, 1, 401-429.
62. Rivero, J.A.; Adunyah, S.E. Sodium butyrate stimulates PKC activation and induces differential expression of certain PKC isoforms during erythroid differentiation. Biochem. Biophys. Res. Commun., 1998, 248, 664-648.
63. Kim, D.; Dan, H.C.; Park, S.; Yang, L.; Liu, Q.; Kaneko, S.; Ning, J.; He, L.; Yang, H.; Sun, M.; Nicosia, S.V.; Cheng, J.Q. AKT/PKB signaling mechanisms in cancer and chemoresistance. Front. Biosci., 2005, 10, 975-987.
64. Nguyen, D.M.; Schrump, W.D.; Tsai, W.S.; Chen, A.; Stewart, J.H. 4th; Steiner, F.; Schrump, D.S. Enhancement of depsipeptide-mediated apoptosis of lung or esophageal cancer cells by flavopiridol: activation of the mitochondria-dependent death-signaling pathway. J. Thorac. Cardiovasc. Surg., 2003, 125, 1132-1142.
65. Almenara, J.; Rosato, R.; Grant, S. Synergistic induction of mitochondrial damage and apoptosis in human leukemia cells by flavopiridol and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA). Leukemia, 2002, 16, 1331-1343.
66. WAF1/CIP1 expression and maturation while reciprocally potentiating apoptosis in human leukemia cells. Mol. Cancer Ther., 2002, 1, 253-266.
67. Nguyen, D.M.; Schrump, W.D.; Chen, G.A.; Tsai, W.; Nguyen, P.; Trepel, J.B.; Schrump, D.S. Abrogation of p21 expression by flavopiridol enhances depsipeptide-mediated apoptosis in malignant pleural mesothelioma cells. Clin. Cancer Res., 2004, 10, 1813-1825.
68. Gao, N.; Dai, Y.; Rahmani, M.; Dent, P.; Grant, S. Contribution of disruption of the nuclear factor-κ;B pathway to induction of apoptosis in human leukemia cells by histone deacetylase inhibitors and flavopiridol. Mol. Pharmacol., 2004, 66, 956-963.
69. Mason, K.A.; Hunter, N.R.; Raju, U.; Ariga, H.; Husain, A.; Valdecanas, D.; Neal, R.; Ang, K.K.; Milas, L. Flavopiridol increases therapeutic ratio of radiotherapy by preferentially enhancing tumor radioresponse. Int. J. Radiat. Oncol. Biol. Phys., 2004, 59, 1181-1189.
70. Kim, S.; Wu, H.G.; Shin, J.H.; Park, H.J.; Kim, I.A.; Kim, I.H. Enhancement of radiation effects by flavopiridol in uterine cervix cancer cells. Cancer Res. Treat., 2005, 37, 191-195.
71. Newcomb, E.W.; Lymberis, S.C.; Lukyanov, Y.; Shao, Y.; Schnee, T.; Devitt, M.; Rosenstein, B.S.; Zagzag, D.; Formenti, S.C. Radiation sensitivity of GL261 murine glioma model and enhanced radiation response by flavopiridol. Cell Cycle, 2006, 5, 93-99.
72. Raju, U.; Nakata, E.; Mason, K.A.; Ang, K.K.; Milas, L. Flavopiridol, a cyclin-dependent kinase inhibitor, enhances radiosensitivity of ovarian carcinoma cells. Cancer Res., 2003, 63, 3263-3267.
73. Chien, M.; Astumian, M.; Liebowitz, D.; Rinker-Schaeffer, C.; Stadler, W.M. In vitro evaluation of flavopiridol, a novel cell cycle inhibitor, in bladder cancer. Cancer Chemother. Pharmacol., 1999, 44, 81-87.
74. Camphausen, K.; Brady, K.J.; Burgan, W.E.; Cerra, M.A.; Russell, J.S.; Bull, E.E.; Tofilon, P.J. Flavopiridol enhances human tumor cell radiosensitivity and prolongs expression of H2AX foci. Mol. Cancer Ther., 2004, 3, 409-416.
75. Dai, Y.; Rahmani, M.; Grant, S. Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and NF-κB-dependent process. Oncogene, 2003, 22, 7108-7122.
76. Yu, C.; Krystal, G.; Dent, P.; Grant, S. Flavopiridol potentiates STI571-induced mitochondrial damage and apoptosis in BCR-ABL-positive human leukemia cells. Clin. Cancer Res., 2002, 8, 2976-2984.
77. Dai, Y.; Rahmani, M.; Pei, X.Y.; Dent, P.; Grant, S. Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms. Blood, 2004, 104, 509-518.
78. Nahta, R.; Iglehart, J.D.; Kempkes, B.; Schmidt, E.V. Rate-limiting effects of Cyclin D1 in transformation by ErbB2 predicts synergy between herceptin and flavopiridol. Cancer Res., 2002, 62, 2267-2271.
79. Nahta, R.; Trent, S.; Yang, C.; Schmidt, E.V. Epidermal growth factor receptor expression is a candidate target of the synergistic combination of trastuzumab and flavopiridol in breast cancer. Cancer Res., 2003, 63, 3626-3631.
80. Zhang, M.; Zhang, Z.; Goldman, C.K.; Janik, J.; Waldmann, T.A. Combination therapy for adult T-cell leukemia-xenografted mice: flavopiridol and anti-CD25 monoclonal antibody. Blood, 2005, 105, 1231-1236.
81. Ali, S.; El-Rayes, B.F.; Aranha, O.; Sarkar, F.H.; Philip, P.A. Sequence dependent potentiation of gemcitabine by flavopiridol in human breast cancer cells. Breast Cancer Res. Treat., 2005, 90, 25-31.
82. Guo, J.; Zhou, A.W.; Fu, Y.C.; Verma, U.N.; Tripathy, D.; Frenkel, E.P.; Becerra, C.R. Efficacy of sequential treatment of HCT116 colon cancer monolayers and xenografts with docetaxel, flavopiridol, and 5-fluorouracil. Acta Pharmacol. Sin., 2006, 27, 1375-1381.
83. Jung, C.P.; Motwani, M.V.; Schwartz, G.K. Flavopiridol increases sensitization to gemcitabine in human gastrointestinal cancer cell lines and correlates with down-regulation of ribonucleotide reductase M2 subunit. Clin. Cancer Res., 2001, 7, 2527-2536.
84. Motwani, M.; Jung, C.; Sirotnak, F.M.; She, Y.; Shah, M.A.; Gonen, M.; Schwartz, G.K. Augmentation of apoptosis and tumor regression by flavopiridol in the presence of CPT-11 in Hct116 colon cancer monolayers and xenografts. Clin. Cancer Res., 2001, 7, 4209-4219.
85. Motwani, M.; Schwartz, G.K. Flavopiridol (Flavo) potentiates the SN-38-induced apopotosis in association with down regulation of cyclin dependent kinase inhibitor p21waf1/cip1 in HCT-116 cells. Proc. Am. Assoc. Cancer Res., 2000, 40, 209.
86. Ambrosini, G.; Seelman, S.L.; Qin, L.X.; Schwartz, G.K. The cyclin-dependent kinase inhibitor flavopiridol potentiates the effects of topoisomerase I poisons by suppressing Rad51 expression in a p53-dependent manner. Cancer Res., 2008, 68, 2312-2320.
87. Wu, K.; D'Amico, M.; Wang, C.; Albanese, C.; Pestell, R.G.; Mani, S. A study of cytotoxic synergy of UCN-01 and flavopiridol in syngeneic pair of cell lines. Invest. New. Drugs., 2005, 23, 299-309.
88. Li, W.; Fan, J.; Bertino, J.R. Selective sensitization of retinoblastoma protein-deficient sarcoma cells to doxorubicin by flavopiridol-mediated inhibition of cyclin-dependent kinase 2 kinase activity. Cancer Res., 2001, 61, 2579-2582.
89. Budak-Alpdogan, T.; Chen, B.; Warrier, A.; Medina, D.J.; Moore, D.; Bertino, J.R. Retinoblastoma tumor suppressor gene expression determines the response to sequential flavopiridol and doxorubicin treatment in small-cell lung carcinoma. Clin. Cancer Res., 2009, 15, 1232-1240.
90. Palacios, C.; Yerbes, R.; López-Rivas, A. Flavopiridol induces cellular FLICE-inhibitory protein degradation by the proteasome and promotes TRAIL-induced early signaling and apoptosis in breast tumor cells. Cancer Res., 2006, 66, 8858-8869.
91. Rosato, R.R.; Dai, Y.; Almenara, J.A.; Maggio, S.C.; Grant, S. Potent antileukemic interactions between flavopiridol and TRAIL/Apo2L involve flavopiridol-mediated XIAP downregulation. Leukemia, 2004, 18, 1780-1788.
92. Iyirhiaro, G.O.; Brust, T.B.; Rashidian, J.; Galehdar, Z.; Osman, A.; Phillips, M.; Slack, R.S.; Macvicar, B.A.; Park, D.S. Delayed combinatorial treatment with flavopiridol and minocycline provides longer term protection for neuronal soma but not dendrites following global ischemia. J. Neurochem., 2008, 105, 703-713.
93. Jorda, E.G.; Verdaguer, E.; Canudas, A.M.; Jiménez, A.; Bruna, A.; Caelles, C.; Bravo, R.; Escubedo, E.; Pubill, D.; Camarasa, J.; Pallàs, M.; Camins, A. Neuroprotective action of flavopiridol, a cyclin-dependent kinase inhibitor, in colchicine-induced apoptosis. Neuropharmacology, 2003, 45, 672-683.
94. Cartee, L.; Maggio, S.C.; Smith, R.; Sankala, H.M.; Dent, P.; Grant, S. Protein kinase C-dependent activation of the tumor necrosis factor receptor-mediated extrinsic cell death pathway underlies enhanced apoptosis in human myeloid leukemia cells exposed to bryostatin 1 and flavopiridol. Mol. Cancer Ther., 2003, 2, 83-93.
95. Lee, Y.K.; Isham, C.R.; Kaufman, S.H.; Bible, K.C. Flavopiridol disrupts STAT3/DNA interactions, attenuates STAT3-directed transcription, and combines with the Jak kinase inhibitor AG490 to achieve cytotoxic synergy. Mol. Cancer Ther., 2006, 5, 138-148.
96. Ge, Y.; Byun, J.S.; De Luca, P.; Gueron, G.; Yabe, I.M.; Sadiq-Ali, S.G.; Figg, W.D.; Quintero, J.; Haggerty, C.M.; Li, Q.Q.; De Siervi, A.; Gardner, K. Combinatorial antileukemic disruption of oxidative homeostasis and mitochondrial stability by the redox reactive thalidomide 2-(2,4-difluoro-phenyl)-4,5,6,7-tetrafluoro-1Hisoindole-1,3(2H)-dione (CPS49) and flavopiridol. Mol. Pharmacol., 2008, 74, 872-883.
97. Hooijberg, J.H.; Broxterman, H.J.; Scheffer, G.L.; Vrasdonk, C.; Heijn, M.; de Jong, M.C.; Scheper, R.J.; Lankelma, J.; Pinedo, H.M. Potent interaction of flavopiridol with MRP1. Br. J. Cancer, 1999, 81, 269-276.
98. Incles, C.M.; Schultes, C.M.; Kelland, L.R.; Neidle, S. Acquired cellular resistance to flavopiridol in a human colon carcinoma cell line involves up-regulation of the telomerase catalytic subunit and telomere elongation. Sensitivity of resistant cells to combination treatment with a telomerase inhibitor. Mol. Pharmacol., 2003, 64, 1101-1108.
99. Schwartz, G.K.; Farsi, K.; Maslak, P.; Kelsen, D.P.; Spriggs, D. Potentiation of apoptosis by flavopiridol in mitomycin-C-treated gastric and breast cancer cells. Clin. Cancer Res., 1997, 3, 1467-1472.
100. Nitta, N.; Sonoda, A.; Seko, A.; Ohta, S.; Nagatani, Y.; Tsuchiya, K.; Otani, H.; Tanaka, T.; Kanasaki, S.; Takahashi, M.; Murata, K. A combination of cisplatin-eluting gelatin microspheres and flavopiridol enhances antitumour effects in a rabbit VX2 liver tumour model. Br. J. Radiol., 2010, 83(989), 428-432.
101. El-Rayes, B.F.; Gadgeel, S.; Parchment, R.; Lorusso, P.; Philip, P.A. A phase I study of flavopiridol and docetaxel Invest. New. Drugs., 2006, 24, 305-310.
102. Schwartz, G.K.; O'Reilly, E.; Ilson, D.; Saltz, L.; Sharma, S.; Tong, W.; Maslak, P.; Stoltz, M.; Eden, L.; Perkins, P.; Endres, S.; Barazzoul, J.; Spriggs, D.; Kelsen, D. Phase I study of the cyclindependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors. J. Clin. Oncol., 2002, 20, 2157-2170.
103. George, S.; Kasimis, B.S.; Cogswell, J.; Schwarzenberger, P.; Shapiro, G.I.; Fidias, P.; Bukowski, R.M. Phase I study of flavopiridol in combination with Paclitaxel and Carboplatin in patients with non-small-cell lung cancer. Clin. Lung. Cancer, 2008, 9, 160-165.
104. Tan, A.R.; Yang, X.; Berman, A.; Zhai, S.; Sparreboom, A.; Parr, A.L.; Chow, C.; Brahim, J.S.; Steinberg, S.M.; Figg, W.D.; Swain, S.M. Phase I trial of the cyclin-dependent kinase inhibitor flavopiridol in combination with docetaxel in patients with metastatic breast cancer. Clin. Cancer Res., 2004, 10, 5038-5047.
105. Shah, M.A.; Kortmansky, J.; Motwani, M.; Drobnjak, M.; Gonen, M.; Yi, S.; Weyerbacher, A.; Cordon-Cardo, C.; Lefkowitz, R.; Brenner, B.; O'Reilly, E.; Saltz, L.; Tong, W.; Kelsen, D.P.; Schwartz, G.K. A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol. Clin. Cancer Res., 2005, 11, 3836-3845.
106. Karp, J.E.; Passaniti, A.; Gojo, I.; Kaufmann, S.; Bible, K.; Garimella, T.S.; Greer, J.; Briel, J.; Smith, B.D.; Gore, S.D.; Tidwell, M.L.; Ross, D.D.; Wright, J.J.; Colevas, A.D.; Bauer, K.S. Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias. Clin. Cancer Res., 2005, 11, 8403-8412.
107. Rathkopf, D.; Dickson, M.A.; Feldman, D.R.; Carvajal, R.D.; Shah, M.A.; Wu, N.; Lefkowitz, R.; Gonen, M.; Cane, L.M.; Dials, H.J.; Winkelmann, J.L.; Bosl, G.J.; Schwartz, G.K. Phase I study of flavopiridol with oxaliplatin and fluorouracil/leucovorin in advanced solid tumors. Clin. Cancer Res., 2009, 15, 7405-7411.
108. Lin, T.S.; Blum, K.A.; Fischer, D.B.; Mitchell, S.M.; Ruppert, A.S.; Porcu, P.; Kraut, E.H.; Baiocchi, R.A.; Moran, M.E.; Johnson, A.J.; Schaaf, L.J.; Grever, M.R.; Byrd, J.C. Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders. J. Clin. Oncol., 2010, 28, 418-423.
109. Karp, J.E.; Smith, B.D.; Levis, M.J.; Gore, S.D.; Greer, J.; Hattenburg, C.; Briel, J.; Jones, R.J.; Wright, J.J.; Colevas, A.D. Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia. Clin. Cancer Res., 2007, 13, 4467-4473.
110. Karp, J.E.; Ross, D.D.; Yang, W.; Tidwell, M.L.; Wei, Y.; Greer, J.; Mann, D.L.; Nakanishi, T.; Wright, J.J.; Colevas, A.D. Timed sequential therapy of acute leukemia with flavopiridol: in vitro model for a phase I clinical trial. Clin. Cancer Res., 2003, 9, 307-315.
111. Karp, J.E.; Blackford, A.; Smith, B.D.; Alino, K.; Seung, A.H.; Bolaños-Meade, J.; Greer, J.M.; Carraway, H.E.; Gore, S.D.; Jones, R.J.; Levis, M.J.; McDevitt, M.A.; Doyle, L.A.; Wright, J.J. Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. Leuk. Res., 2009, [Epub ahead of print]
112. Carvajal, R.D.; Tse, A.; Shah, M.A.; Lefkowitz, R.A.; Gonen, M.; Gilman-Rosen, L.; Kortmansky, J.; Kelsen, D.P.; Schwartz, G.K.; O'Reilly, E.M. A phase II study of flavopiridol (Alvocidib) in combination with docetaxel in refractory, metastatic pancreatic cancer. Pancreatology, 2009, 9, 404-409.